Harbin Pharmaceutical Group (600664) Fair Value & Analysis
Healthcare · CN · Market cap 8.0B CNY
Analysis
Harbin Pharmaceutical Group (600664) currently trades at ¥3.08, while our model-based Fair Value estimate is ¥4.40 — implying the stock looks roughly 42.9% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, human erythropoietin injections, iron vitamin B12 oral solutions, ceftriaxone sodium injections, Qufenggutong gel cream, GNC Vitapak nutrition package, lacidipine tablets, GNC fish oil, GNC children's liquid calcium magnesium zinc IV, and penicillin and cephalosporin antibiotic preparations. …
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.